BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36467342)

  • 1. High expression of aurora kinase B predicts poor prognosis in hepatocellular carcinoma after curative surgery and its effects on the tumor microenvironment.
    Zhao H; Wang Y; Yang Z; Wei W; Cong Z; Xie Y
    Ann Transl Med; 2022 Nov; 10(21):1168. PubMed ID: 36467342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of Aurora Kinase B Is Correlated with Diagnosis and Poor Prognosis in Hepatocellular Carcinoma.
    Zhang J; Ma J; Li Y; An Y; Du W; Yang Q; Huang M; Cai X
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of Aurora B and alternative variant forms in hepatocellular carcinoma and adjacent tissue.
    Yasen M; Mizushima H; Mogushi K; Obulhasim G; Miyaguchi K; Inoue K; Nakahara I; Ohta T; Aihara A; Tanaka S; Arii S; Tanaka H
    Cancer Sci; 2009 Mar; 100(3):472-80. PubMed ID: 19134008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AURKB targets DHX9 to promote hepatocellular carcinoma progression via PI3K/AKT/mTOR pathway.
    Zhu G; Luo L; He Y; Xiao Y; Cai Z; Tong W; Deng W; Xie J; Zhong Y; Hu Z; Shan R
    Mol Carcinog; 2024 Jun; ():. PubMed ID: 38874176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors for hepatocellular carcinoma recurrence after microwave ablation.
    Moteleub HNAE; Moety AAAE; Baddour NM; Shendidi AAE
    Clin Exp Hepatol; 2020 Jun; 6(2):77-84. PubMed ID: 32728623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Edmondson-Steiner grade: A crucial predictor of recurrence and survival in hepatocellular carcinoma without microvascular invasio.
    Zhou L; Rui JA; Zhou WX; Wang SB; Chen SG; Qu Q
    Pathol Res Pract; 2017 Jul; 213(7):824-830. PubMed ID: 28554743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High aurora kinase expression identifies patients with muscle-invasive bladder cancer who have poor survival after neoadjuvant chemotherapy.
    Burgess EF; Livasy C; Trufan S; Hartman A; Guerreri R; Naso C; Clark PE; Grigg C; Symanowski J; Raghavan D
    Urol Oncol; 2019 Dec; 37(12):900-906. PubMed ID: 31597600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased CDCA2 Level Was Related to Poor Prognosis in Hepatocellular Carcinoma and Associated With Up-Regulation of Immune Checkpoints.
    Tang M; Liao M; Ai X; He G
    Front Med (Lausanne); 2021; 8():773724. PubMed ID: 35372372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MARCKS on Tumor-Associated Macrophages is Correlated with Immune Infiltrates and Poor Prognosis in Hepatocellular Carcinoma.
    Ren X; Ju Y; Wang C; Wei R; Sun H; Zhang Q
    Cancer Invest; 2021 Oct; 39(9):756-768. PubMed ID: 34279157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of Stress-Induced Protein Kinase CK1 Delta is associated with a Poor Prognosis for patients with Hepatocellular Carcinoma.
    Zhang H; Qiu C; Zeng H; Zhu W; Lyu W; Lao X
    Genet Test Mol Biomarkers; 2021 Jul; 25(7):504-514. PubMed ID: 34280005
    [No Abstract]   [Full Text] [Related]  

  • 11. DCK is a promising prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma.
    Song D; Wang Y; Zhu K; Tian L; Gao Q; Zhou J; Fan J; Wang X
    World J Surg Oncol; 2020 Jul; 18(1):176. PubMed ID: 32690026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated Small Nuclear Ribonucleoprotein Polypeptide an Expression Correlated With Poor Prognosis and Immune Infiltrates in Patients With Hepatocellular Carcinoma.
    Zhang Y; Wang X; Wang H; Jiang Y; Xu Z; Luo L
    Front Oncol; 2022; 12():893107. PubMed ID: 35860579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
    Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
    World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Differential analysis of gene expression profiles in hepatocellular carcinoma patients with high and low levels of alpha-fetoprotein].
    Wang XJ; Shen RF; Wang X; Wang YR; Xiao T
    Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):396-402. PubMed ID: 32482029
    [No Abstract]   [Full Text] [Related]  

  • 15. Risk factors of microvascular invasion, portal vein tumor thrombosis and poor post-resectional survival in HBV-related hepatocellular carcinoma.
    Zhou L; Rui JA; Wang SB; Chen SG; Qu Q
    Hepatogastroenterology; 2014 Sep; 61(134):1696-703. PubMed ID: 25436365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
    Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
    World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PPM1D is a potential prognostic biomarker and correlates with immune cell infiltration in hepatocellular carcinoma.
    Yu Z; Song Y; Cai M; Jiang B; Zhang Z; Wang L; Jiang Y; Zou L; Liu X; Yu N; Mao X; Peng C; Liu S
    Aging (Albany NY); 2021 Sep; 13(17):21294-21308. PubMed ID: 34470916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A scoring model combining serum alpha-fetoprotein and tumor size and number predicts prognosis in hepatitis B virus-related hepatocellular carcinoma patients after curative hepatectomy.
    Wei B; Chen JS; Yang SL; Chen GG; He H
    Transl Cancer Res; 2019 Aug; 8(4):1438-1448. PubMed ID: 35116886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of POLA2 in hepatocellular carcinoma is involved in immune infiltration and predicts a poor prognosis.
    Liu L; Wang Q; Wu L; Zhang L; Huang Y; Yang H; Guo L; Fang Z; Wang X
    Cancer Cell Int; 2023 Jul; 23(1):138. PubMed ID: 37452331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors of recurrence and poor survival in curatively resected hepatocellular carcinoma with microvascular invasion.
    Zhou L; Wang SB; Chen SG; Qu Q; Rui JA
    Adv Clin Exp Med; 2020 Jul; 29(7):887-892. PubMed ID: 32750753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.